573673-43-5

Basic information

• Product Name: 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-, Methyl ester
• Synonyms: 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-, Methyl ester;Methyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)picolinate
• CAS NO: 573673-43-5
• Molecular Formula: C₂₁H₁₅ClF₃N₃O₄
• Molecular Weight: 465.8097096
• Mol File: 573673-43-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 228-230 °C
• Boiling Point: 494.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.469±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.89±0.70(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-, Methyl ester(573673-43-5)
• EPA Substance Registry System: 2-Pyridinecarboxylic acid, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-, Methyl ester(573673-43-5)

Safety Data

• Hazardous Substances Data: 573673-43-5(Hazardous Substances Data)

Upstream product

• 1012058-77-3 4‐(4‐aminophenoxy)‐2‐pyridine carboxylic acid 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 123-30-8 4-amino-phenol 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 1097726-89-0 tert-butyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)picolinate 
• 98-98-6 2-Picolinic acid 
• 67-56-1 methanol 
• 1012058-78-4 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxylic acid 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 1097726-88-9 tert-butyl 4-(4-aminophenoxy)picolinate 
• 220000-86-2 tert-butyl 4-chloropyridine-2-carboxylate 
• 5470-22-4 4-chloropicolinic acid 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 

Downstream Products

• 284461-74-1 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide 
• 1012058-78-4 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxylic acid 
• 1012058-93-3 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(2-(hydroxymethyl)pyridin-4-yloxy)phenyl)urea 
• 1130115-44-4 N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl-d₃)aminoformyl)-4-pyridyloxy)phenyl)urea 
• 1333386-17-6 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxyl)-2-(N-1’,1’,1’-trideuteromethyl)pyridine amide p-toluenesulfonate 
• 1610930-10-3 1-(4-(2-(2-(3-fluorophenylacetyl)hydrazinocarbonyl)pyridin-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-11-4 1-(4-(2-(2-(4-fluorophenylacetyl)hydrazinocarbonyl)pyridine-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-12-5 C₂₈H₁₉ClF₅N₅O₄ 
• 1610930-13-6 1-(4-(2-(2-(3-fluoro-4-bromophenylacetyl)hydrazinylcarbonyl)pyridinyl-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-14-7 1-(4-(2-(2-(2,3-difluorophenylacetyl)hydrazinocarbonyl)pyridine-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-15-8 1-(4-(2-(2-(3-chloro-4-hydroxyphenylacetyl)hydrazinocarbonyl)pyridine-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-16-9 1-(4-(2-(2-(2-methoxyphenylacetyl)hydrazinocarbonyl)pyridine-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-17-0 1-(4-(2-(2-(3,4-dimethoxyphenylacetyl)hydrazinocarbonyl)pyridine-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1610930-18-1 1-(4-(2-(2-(4-ethoxyphenylacetyl)hydrazinocarbonyl)pyridine-4-yloxy)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 

Relevant articles and documents

Introduction of mercaptoethyl at sorafenib pyridine‐2‐amide motif as a potentially effective chain to further get sorafenib‐PEg‐DGL

The crystal structure of the sorafenib and B‐RAF complex indicates that the binding cavity occupied by the pyridine‐2‐carboxamide in sorafenib has a large variable space, making it a reasonable modification site. In order to identify novel compounds with anti‐cancer activity, better safety and polar groups for further application, five sorafenib analogs with new pyridine‐2‐amide side chains were designed and synthesized. Preliminary pharmacologic studies showed that these compounds displayed much lower toxicities than that of sorafenib. Among them, compound 10b bearing mercaptoethyl group kept relevant antiproliferation potency compared to sorafenib in Huh7 and Hela cell lines with values of IC50 58.79 and 63.67 μM, respectively. As a small molecule inhibitor targeting protein tyrosine kinases, thiol in compound 10b would be an active group to react with maleimide in a mild condition for forming nanoparticles Sorafenib‐PEG‐DGL, which could be developed as a delivery vehicle to improve the concentration of anti‐tumor therapeutic agents in the target cancer tissue and reduce side effects in the next study.

Synthesis and in vitro cytotoxic activities of sorafenib derivatives

A series of novel sorafenib derivatives have been designed and synthesized. The cytotoxic activities of these compounds were tested in three tumor cell lines. Most of the compounds showed potent antiproliferative activity against the tested cell lines with IC50 = 0-20 μmol/L. Some compounds demonstrated competitive antiproliferative activities to sorafenib against all three cancer cell lines. Among them, compound 5g demonstrated significant inhibitory activity against A549, ACHN and MDA-MB-231 cell lines with IC 50 values of 1.29, 1.99, 3.11 μmol/L, respectively.

RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.